Avidity Biosciences Inc
NASDAQ:RNA
Operating Margin
Avidity Biosciences Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Avidity Biosciences Inc
NASDAQ:RNA
|
4.1B USD |
-4 853%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
337.9B USD |
30%
|
|
| US |
|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 834%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
165.8B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
141.4B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122.6B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
130.4B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
61.9B USD |
29%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Avidity Biosciences Inc
Glance View
Avidity Biosciences Inc. is a biopharmaceutical company on the cutting edge of science devoted to treating severe diseases through breakthrough technology. Founded in 2012, Avidity's primary innovation lies in its pioneering platform known as the Antibody Oligonucleotide Conjugates (AOCs). This inventive approach merges the precision-targeting abilities of monoclonal antibodies with the potent gene-modulating capabilities of oligonucleotides. By effectively leveraging these two technologies, Avidity aims to address previously undruggable genetic conditions, providing new therapeutic avenues for diseases such as muscular dystrophies and other serious genetic disorders. The company channels its efforts into discovering, developing, and ultimately bringing these transformative therapies to market. The economic lifeline of Avidity Biosciences is deeply intertwined with its robust research and development pipeline, strategically focused partnerships, and potential revenue streams emanating from successful clinical trials. By innovating within the realm of RNA therapeutics, Avidity taps into collaborations with major pharmaceutical entities, further bolstering its financial standing. For instance, its collaborations often entail upfront technology access fees and potential milestone payments as drug candidates progress through clinical stages. Avidity's long-term financial model rests on the successful commercialization of its unique AOCs. Through these multifaceted operations, the company aims to generate sustainable revenue while making significant impacts in precision medicine, exemplifying a model that merges groundbreaking science with strategic industry alliances.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Avidity Biosciences Inc's most recent financial statements, the company has Operating Margin of -4 853.4%.
You don't have any saved screeners yet